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here are many clinical presentations and
subtypes of alopecia areata (AA).1,2 One
subtype, the ophiasis form, affects the occip-
ital and parietal scalp and is often more resistant to
treatment than AA monolocularis and AA multi-
locularis (ie, patchy AA).2 I present a case of a patient
with corticosteroid-resistant ophiasis AA who had
prompt regrowth with platelet-rich plasma (PRP)
injections.
A 41-year-oldwomanwithAA and bipolar disorder
presented with concerns about poor response to
intralesional triamcinolone acetonide injections (3
treatment sessions of 5 mg/mL; total 3 mL) and severe
debilitating alterations in mood in the immediate
weeks after each treatment session. Previous treat-
ments includedminoxidil and topical steroidswithout
effect. The patient did not wish to use systemic
treatments nor contact therapy (diphencyprone, an-
thralin). A history of patchy AAwas present for over a
decade but had been worsening in the past several
years. Ophiasis-type AA was present for 2 years.
Eyebrows, eyelashes, and nails were unaffected.
Current medication included lithium, quetiapine,
and lurasidone. Blood test results were normal,
including platelet concentration 201 3 109/L, ferritin
72g/L, and thyroid-stimulatinghormone3.42mIU/L.
Treatment was administered with autologous PRP
(Arthrex Angel System, Arthrex Inc, Naples, FL) at a
concentration 3.5 times above baseline using a 2%
hematocrit setting. The patient’s last steroid injection
was 4 months prior. Briefly, 120 mL of blood was
obtained from the patient using a 19-gauge butterfly
needle and spun according to manufacturer’sthe University of Toronto Hair Clinic, Women’s College
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oronto.ca.instructions. The scalp was anesthetized with 1%
lidocaine with 1:100,000 epinephrine with 0.1-mL
injections made every 1 cm with use of vibratory
distracting device to minimize discomfort. Thirty
minutes later PRP was mixed with platelet-poor
plasma to achieve a final platelet concentration 3.5
times above baseline. A total of 9 mL of PRP was
injected into the 40-cm2 occipital area using a
25-gauge needle. Additional methods of platelet
activation used by some physicians, including
coadministration of thrombin or calcium gluconate
or use of a dermaroller device, were not used in the
protocol for this patient.
The procedure was well tolerated. Mild tender-
ness was present on day of the procedure and on the
following 2 days but controlled with acetaminophen.
Hair regrowth was noted by month 1 with robust
regrowth of hairs measuring 2.8 cm by month 3
(Fig 1). The patient had no mood alterations at any
period after administration of PRP.
PRP represents a new and potentially effective
treatment option for AAwith minimal associated side
effects. This case offers 2 important points: the first
being the potential of PRP to treat steroid-resistant
forms of AA and the second being the option to use
PRP to treat AA in patients who develop limiting side
effects from steroid injections.
The mechanism of PRP in the treatment of AA
remains unknown, but is likely a combination of
growth-stimulatory and immune-modulatory mech-
anisms. PRP is known to contain more than 20
growth factors3 and has beneficial effects on wound
healing and hair growth.4JAAD Case Reports 2015;1:305-7.
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Fig 1. Hair regrowth in ophiasis-type alopecia areata after platelet-rich plasma (PRP) injection.
Occipital hair loss before treatment (A) and occipital hair regrowth 3 months after
administration of PRP at a concentration 3.5 times above baseline (B).
Table I. Side effects of platelet-rich plasma
injections
Step in procedure Side effect
Blood draw
(from antecubital fossa)
d Minor discomfort with
blood draw
d Vasovagal reactions
d Nerve injury/damage (rare)
d Local bruising
Administration of local
anesthetics to scalp
(lidocaine with
epinephrine) while
centrifuging PRP
d Minor pain and burning
d Pinpoint bleeding
d Local anesthetic
reactions (rare)
Administration of PRP d Minor discomfort if areas
are not fully anesthetized
d Pinpoint bleeding
Early recovery period
(first 24-48 h)
d Minor pain in scalp
d Forehead swelling
d Scalp redness (rare)
Late recovery (first 2 mo) d Telogen effluvium
(uncommon)
PRP, Platelet-rich plasma.
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warrants further study. A recent randomized
double-blind, placebo-controlled half-head study
of 45 patients with patchy AA (AA multilocularis)
demonstrated that PRP was effective, and provided
significantly better regrowth than 2.5 mg/mL triam-
cinolone acetonide.5 However, that study did not
address the role of PRP in ophiasis-type AA, which is
more challenging to treat than patchy AA. Indeed
many individuals with ophiasis-type AA, including
the patient described herein, do not respond to
steroid injections. The effectiveness of PRP in
ophiasis-type AA and whether PRP is consistently
more effective than triamcinolone acetonide in
ophiasis-type AA remains unknown but warrants
further study. Furthermore, the role of PRP in casesof steroid-resistant AA also warrants additional
study.
Side effects from steroid injections are generally
transient in nature and include local cutaneous
effects such as atrophy, telangiectasia, and pig-
mentation changes. Systemic effects appear to be
uncommon with steroid injections but studies
addressing the frequency of these issues in patients
with AA receiving scalp injections are lacking. In
other fields of medicine, it is clear that even a
single dose of steroid in the nonoral route can lead
to mood changes. For example, Fishman et al6
published a report of corticosteroid-induced mania
after a single regional application at the celiac
plexus.
When administered via the oral route, mood
changes are not uncommon. Naber et al7 reported
that 26% of patients who were initially free of
psychiatric illness and received short courses of
high-dose prednisone for ophthalmologic disorders
developed mania and 10% developed depression.
The Boston Collaborative Drug Surveillance
Program8 found that severe psychiatric illness
occurred with a frequency of 1.3%. Mood-related
side effects from oral steroids appear to be dose
dependent. Given the high prevalence of mood
disorders such as major depressive disorder9 and
anxiety10 in patients with AA, further study is needed
to evaluate the benefits of PRP for those who
experience mood changes with steroid injections.
Currently, it appears that administration of PRP is
not associated with many of the side effects of
corticosteroids (Table I). Indeed, PRP administration
to 45 patients with AA was also not associated with
side effects.5 The patient presented here did not
experience side effects other than transient discom-
fort. Importantly, she did not experience any of the
mood changes she had previously experienced with
steroid injections. Further study is needed to
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and in the treatment of AA.
REFERENCES
1. Hordinksy MK. Overview of alopecia areata. J Investig Dermatol
Symp Proc. 2013;16:S13-S15.
2. Shapiro J. Current treatment of alopecia areata. J Investig
Dermatol Symp Proc. 2013;16:S42-S44.
3. Takikawa M, Nakamura S, Nakamura A, et al. Enhanced effect
of platelet rich plasma containing a new carrier on hair
growth. Dermatol Surg. 2011;37:1721-1729.
4. Li ZJ, Choi HI, Choi DK, et al. Autologous platelet-rich plasma: a
potential therapeutic tool for promoting hair growth. Derma-
tol Surg. 2012;38:1040-1046.
5. Trink A, Sorbellini E, Bezzola P, et al. A randomized, double-
blind, placebo- and active-controlled, half-head study toevaluate the effects of platelet rich plasma on alopecia areata.
Br J Dermatol. 2013;169:690-694.
6. Fishman SM, Catarau EM, Sachs G, Stojanovic M, Borsook D.
Corticosteroid-induced mania after a single regional applica-
tion at the celiac plexus. Anesthesiology. 1996;85:1194-1196.
7. Naber D, Sand P, Heigl B. Psychopathological and neuropsy-
chological effects of 8-days’ corticosteroid treatment: a pro-
spective study. Psychoneuroendocrinology. 1996;21:25-31.
8. The Boston Collaborative Drug Surveillance Program. Acute
adverse reactions to prednisone in relation to dosage. Clin
Pharmacol Ther. 1972;13:694-698.
9. Colon EA, Popkin MK, Callies AL, Dessert NJ, Hordinsky MK.
Lifetime prevalence of psychiatric disorders in patients with
alopecia areata. Compr Psychiatry. 1991;32:2245-2251.
10. Koo JY, Shellow WV, Hallman CP, Edwards JE. Alopecia areata
and increased prevalence of psychiatric disorders. Int J
Dermatol. 1994;33:849-850.
